Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology
Goldberg, Richard M; Adams, Richard; Buyse, Marc; Eng, Cathy; Grothey, Axel; André, Thierry; Sobrero, Alberto F; Lichtman, Stuart M; Benson, Al B; Punt, Cornelis J A; Maughan, Tim; Burzykowski, Tomasz; Sommeijer, Dirkje; Saad, Everardo D; Shi, Qian; Coart, Elisabeth; Chibaudel, Benoist; Koopman, Miriam; Schmoll, Hans-Joachim; Yoshino, Takayuki; Taieb, Julien; Tebbutt, Niall C; Zalcberg, John; Tabernero, Josep; Van Cutsem, Eric; Matheson, Alastair; de Gramont, Aimery
(2022) Journal of the National Cancer Institute, volume 114, issue 6, pp. 819 - 828
(Article)
Abstract
Meta-Analysis based on individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from multiple trials. Hitherto, its principal application has been in questions of clinical management, but an increasingly important use is in clarifying trials methodology, for instance in the selection of endpoints, as
... read more
discussed in this review. In oncology, the Aide et Recherche en Cancerologie Digestive (ARCAD) Metastatic Colorectal Cancer Database is a leader in the use of IPD-based meta-Analysis in methodological research. The ARCAD database contains IPD from more than 38 000 patients enrolled in 46 studies and continues to collect phase III trial data. Here, we review the principal findings of the ARCAD project in respect of endpoint selection and examine their implications for cancer trials. Analysis of the database has confirmed that progression-free survival (PFS) is no longer a valid surrogate endpoint predictive of overall survival in the first-line treatment of colorectal cancer. Nonetheless, PFS remains an endpoint of choice for most first-line trials in metastatic colorectal cancer and other solid tumors. Only substantial PFS effects are likely to translate into clinically meaningful benefits, and accordingly, we advocate an oncology research model designed to identify highly effective treatments in carefully defined patient groups. We also review the use of the ARCAD database in assessing clinical response including novel response metrics and prognostic markers. These studies demonstrate the value of IPD as a tool for methodological studies and provide a reference point for the expansion of this approach within clinical cancer research.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Clinical Trials, Phase III as Topic, Colorectal Neoplasms/drug therapy, Databases, Factual, Humans, Meta-Analysis as Topic, Neoplasms, Second Primary, Research Design, Treatment Outcome, Oncology, Cancer Research, Review, Journal Article
ISSN: 0027-8874
Publisher: Oxford University Press
Note: Publisher Copyright: © 2022 The Author(s) 2021. Published by Oxford University Press. All rights reserved.
(Peer reviewed)